A lentiviral vector-based adenovirus fiber-pseudotyping approach for expedited functional assessment of candidate retargeted fibers

Journal of Gene Medicine

Volumn 11, Issue 11, 2009, Pages 990-1004

  Uil, Taco G ^a   De Vrij, Jeroen ^a   Vellinga, Jort ^a,e   Rabelink, Martijn J W E ^a   Cramer, Steve J ^a   Chan, On Ying A ^a,f   Pugnali, Margherita ^b   Magnusson, Maria ^c   Lindholm, Leif ^c   Boulanger, Pierre ^d   Hoeben, Rob C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ENEA   (Italy)

^c Got A Gene AB ^*  (Sweden)

^d UNIVERSITÉ DE LYON   (France)

^e CRUCELL HOLLAND BV   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Adenovirus targeting; Capsid modification; Fiber; Lentiviral vector; scFv

Indexed keywords

ADENOVIRUS VECTOR; LENTIVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PSEUDOTYPING; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ADENOVIRIDAE; CELLS, CULTURED; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; LENTIVIRUS; SINGLE-CHAIN ANTIBODIES; TRANSDUCTION, GENETIC;

ADENOVIRIDAE; MIRIDAE;

EID: 72949101496     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1395     Document Type: Article

References (72)

1. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006; 13: 830-844.
2. Legrand V, Leissner P, Winter A, Mehtali M, Lusky M. Transductional targeting with recombinant adenovirus vectors. Curr Gene Ther 2002; 2: 323-339.
3. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
4. Nicklin SA, Wu E, Nemerow GR, Baker AH. The influence of adenovirus fiber structure and function on vector development for gene therapy. Mol Ther 2005; 12: 384-393.
5. Wu H, Curiel DT. Fiber-modified adenoviruses for targeted gene therapy. Methods Mol Biol 2008; 434: 113-132.
6. Vellinga J, Rabelink MJ, Cramer SJ, et al. Spacers increase the accessibility of peptide ligands linked to the carboxyl terminus of adenovirus minor capsid protein IX. J Virol 2004; 78: 3470-3479.
7. de Vrij J, Uil TG, van den Hengel SK, et al. Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a singlechain T-cell receptor with minor capsid protein IX. Gene Ther 2008.
8. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 2002; 76: 6893-6899.
9. Wu H, Han T, Belousova N, et al. Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 2005; 79: 3382-3390.
10. Hedley SJ, Chen J, Mountz JD, et al. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol Immunother 2006; 55: 1412-1419.
11. Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol 1996; 70: 6839-6846.
12. Stevenson SC, Rollence M, Marshall-Neff J, McClelland A. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997; 71: 4782-4790.
13. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996; 70: 2116-2123.
14. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14: 1570-1573.
15. Wickham TJ, Tzeng E, Shears LL, et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221-8229.
16. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-9713.
17. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844-1852.
18. Hesse A, Kosmides D, Kontermann RE, Nettelbeck DM. Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain. J Virol 2007; 81: 2688-2699.
19. Uil TG, Seki T, Dmitriev I, et al. Generation of an adenoviral vector containing an addition of a heterologous ligand to the serotype 3 fiber knob. Cancer Gene Ther 2003; 10: 121-124.
20. Nakamura T, Sato K, Hamada H. Reduction of natural adenovirus tropism to the liver by both ablation of fibercoxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J Virol 2003; 77: 2512-2521.
21. van Beusechem VW, van Rijswijk AL, van Es HH, Haisma HJ, Pinedo HM, Gerritsen WR. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther 2000; 7: 1940-46.
22. Schagen FH, Wensveen FM, Carette JE, Dermody TS, Gerritsen WR, van Beusechem VW. Genetic targeting of adenovirus vectors using a reovirus sigma 1-based attachment protein. Mol Ther 2006; 13: 997-1005.
23. Krasnykh V, Belousova N, Korokhov N, Mikheeva G, Curiel DT. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J Virol 2001; 75: 4176-4183.
24. Magnusson MK, Hong SS, BoulangerP, LindholmL. Genetic retargeting of adenovirus: novel strategy employing 'deknobbing' of the fiber. J Virol 2001; 75: 7280-7289.
25. Von Seggern DJ, Huang S, Fleck SK, Stevenson SC, Nemerow GR. Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells. J Virol 2000; 74: 354-362.
26. Jakubczak JL, Rollence ML, Stewart DA, et al. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptorbearing cells. J Virol 2001; 75: 2972-2981.
27. Fallaux FJ, Kranenburg O, Cramer SJ, et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
28. Legrand V, Spehner D, Schlesinger Y, Settelen N, Pavirani A, Mehtali M. Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber. J Virol 1999; 73: 907-919.
29. Magnusson MK, Henning P, Myhre S, et al. Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Ther 2007; 14: 468-479.
30. Wikman M, Steffen AC, Gunneriusson E, et al. Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng Des Sel 2004; 17: 455-462.
31. Maizel JV Jr, White DO, Scharff MD. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7 A, and 12. Virology 1968; 36: 115-125.
32. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
33. Hanahan D. Studies on transformation of Escherichia coli with plasmids. J Mol Biol 1983; 166: 557-580.
34. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805-4810.
35. Barry SC, Harder B, Brzezinski M, FlintL Y, Seppen J, Osborne WR. Lentivirus vectors encoding both central polypurine tract and posttranscriptional regulatory element provide enhanced transduction and transgene expression. Hum Gene Ther 2001; 12: 1103-1108.
36. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
37. Magnusson MK, Hong SS, Henning P, Boulanger P, Lindholm L. Genetic retargeting of adenovirus vectors: functionality of targeting ligands and their influence on virus viability. J Gene Med 2002; 4: 356-370.
38. Toes RE, Hoeben RC, van der Voort EI, et al. Protective antitumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 1997; 94: 14660-14665.
39. Galeffi P, Lombardi A, Pietraforte I, et al. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med 2006; 4: 39.
40. Carlotti F, Bazuine M, Kekarainen T, et al. Lentiviral vectors efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol Ther 2004; 9: 209-217.
41. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
42. Hong JS, Engler JA. The amino terminus of the adenovirus fiber protein encodes the nuclear localization signal. Virology 1991; 185: 758-767.
43. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001; 61: 4750-4755.
44. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-1578.
45. Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirusadenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909-7915.
46. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
47. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
48. Zhang Y, Feigenblum D, Schneider RJ. A late adenovirus factor induces eIF-4E dephosphorylation and inhibition of cell protein synthesis. J Virol 1994; 68: 7040-7050.
49. Logan J, Shenk T. Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection. Proc Natl Acad Sci USA 1984; 81: 3655-3659.
50. SheayW, Nelson S, Martinez I, Chu TH, Bhatia S, Dornburg R. Downstream insertion of the adenovirus tripartite leader sequence enhances expression in universal eukaryotic vectors. Biotechniques 1993; 15: 856-862.
51. Von Seggern DJ, Kehler J, Endo RI, Nemerow GR. Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein. J Gen Virol 1998; 79: 1461-1468.
52. Von Seggern DJ, Chiu CY, Fleck SK, Stewart PL, Nemerow GR. A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. J Virol 1999; 73: 1601-1608.
53. Galeffi P, Lombardi A, Donato MD, et al. Expression of single-chain antibodies in transgenic plants. Vaccine 2005; 23: 1823-1827.
54. Lombardi A, Sperandei M, Cantale C, Giacomini P, Galeffi P. Functional expression of a single-chain antibody specific for the HER2 human oncogene in a bacterial reducing environment. Protein Expr Purif 2005; 44: 10-15.
55. Belousova N, Mikheeva G, Gelovani J, Krasnykh V. Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer. J Virol 2008; 82: 630-637.
56. Hedley SJ, Auf der MA, Hohn S, et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 2006; 13: 88-94.
57. Vellinga J, de Vrij J, Myhre S, et al. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther 2007; 14: 664-670.
58. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 2008; 132: 397-409.
59. Kalyuzhniy O, Di Paolo NC, Silvestry M, et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 2008; 105: 5483-5488.
60. Russell SJ, Hawkins RE, Winter G. Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 1993; 21: 1081-1085.
61. Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 2008; 82: 10153-10161.
62. Conner J, Braidwood L, Brown SM. A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Gene Ther 2008.
63. Somia NV, Zoppe M, Verma IM. Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proc Natl Acad Sci USA 1995; 92: 7570-7574.
64. Martineau P, Jones P, Winter G. Expression of an antibody fragment at high levels in the bacterial cytoplasm. J Mol Biol 1998; 280: 117-127.
65. Proba K, Worn A, Honegger A, Pluckthun A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J Mol Biol 1998; 275: 245-253.
66. Worn A, Pluckthun A. Different equilibrium stability behavior of ScFv fragments: identification, classification, and improvement by protein engineering. Biochemistry 1999; 38: 8739-8750.
67. Visintin M, Settanni G, Maritan A, Graziosi S, Marks JD, Cattaneo A. The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodies. J Mol Biol 2002; 317: 73-83.
68. Auf der MA, Escher D, Barberis A. Antigen-independent selection of stable intracellular single-chain antibodies. FEBS Lett 2001; 508: 407-412.
69. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6578.
70. Zahnd C,Wyler E, Schwenk JM, et al. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 2007; 369: 1015-1028.
71. Binz HK, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23: 1257-1268.
72. Myhre S, Henning P, Friedman M, Stahl S, Lindholm L, Magnusson MK. Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther 2008.